~~<i id='D02D12B7A7'><strike id='D02D12B7A7'><tt id='D02D12B7A7'><pre id='D02D12B7A7'></pre></tt></strike></i>~~

Home» leisure time» focus

focus

author：explore 2025-10-04 09:11:38 Page View：4776

A European regulatory panel has recommended against approval of a lung cancer drug made by Mirati Therapeutics, the company said Friday.

Mirati said it will appeal the negative opinion of the drug, called Krazati, issued by a committee of the European Medicines Agency that met this week. But for now, the adverse decision is likely to be adopted by European regulators and prevent the company from marketing the pill in Europe.

Krazati works by blocking a specific type of KRAS alteration called G12C, found in approximately 13% of lung tumors.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Palestinian attacker wounds 8 in Tel Aviv as Israel presses on with West Bank operation
Next article： Guidelines to prevent youth baseball injuries need more muscle

focus

Jerome Adams on the need for new antivirals for Covid

PaxlovidtabletsamplesbeinginspectedinFreiburg,Germany.PfizerviaAPTheU.S.Covid-19Public HealthEmergen

10 states plan to sue EPA over standards for residential wood

DonSakischecksthefireinhisRitewaywoodstoveathishomeonJan.23,2018,inPalmer,Alaska.Sakisandhisfamilyha

Moonlake's readout produced a cash windfall. Risks remain

MollyFerguson/STATFortwodaysstartingonSunday,MoonlakeImmunotherapeuticshappilycrunchednumbersandshar

For one rare type of lung cancer, Pfizer pill reduces progression by 81%

AP/BusinessWireTherearealotofreasonswhyupdateddataonPfizer’sLorbrena,atreatmentfornon-smallcelllungc